AZTR jumps 38.5% as EPS revision boosts small-cap healthcare AI play
AZTR surged 38.5% from $0.13 to $0.18 in the six sessions after analysts raised its next-year EPS estimate from 59.6% to 68.0% on August 21, the strongest gain of the five stocks highlighted. CRWD leapt 14.5% to $218.40 following record quarterly results, while EBS climbed 16.3% to $5.91 on the back of a 191.0% EPS growth outlook. The technology trio (CRWD, BRZE, HUBS) advanced between 8.6% and 14.5%, reflecting persistent investor appetite for AI/cloud software names.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| AZTR | Healthcare | 2026-08-21 | +8.4pp | +38.5% |
| EBS | Healthcare | 2026-08-21 | N/A | +16.3% |
| CRWD | Technology | 2026-08-24 | N/A | +14.5% |
| BRZE | Technology | 2026-08-25 | N/A | +12.1% |
| HUBS | Technology | 2026-08-21 | N/A | +8.6% |
Why did AZTR stock jump in August 2026?
AZTR jumped 38.5% (from $0.13 to $0.18) between August 21 and August 27, after analysts raised its next-year EPS growth estimate to 68.0% from 59.6%.
The stock, a micro-cap clinical-stage healthcare name, also rode a broader biotech uptick as the Russell 2000 struggled but small-cap biotechs recovered. With no company-specific news, the EPS revision itself served as a value signal at a time when the PCE index running hot was pressuring risk sentiment. That estimate upgrade from a single sell-side desk was enough to move a stock in this price zone.
AZTR EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: AZTR
Why did AZTR jump recently?
AZTR climbed 38.5% from $0.13 to $0.18 after analysts raised its next-year EPS growth estimate to 68.0% from 59.6% on August 21.
Is AZTR a buy after the rally?
The 38.5% gain reflects a positive EPS revision, but the stock remains sub-$1 and the next-year EPS growth estimate of 68.0% is still unproven for a clinical-stage healthcare company.
What is AZTR's EPS growth estimate?
AZTR's next-year EPS growth estimate was raised to 68.0% from 59.6%, a 8.4-percentage-point upward revision.
Why did EBS stock jump in August 2026?
EBS jumped 16.3% (from $5.08 to $5.91) after its next-year EPS growth estimate stood at 191.0% on August 21, a revision that flagged massive earnings expansion potential.
The vaccine maker caught a bid as the broader biotech sector recovered, and the absence of negative news amplified the positive estimate signal. Investors saw the 191.0% growth as evidence that EBS is past its debt-driven trough and moving toward normalized profitability. That dramatic EPS uplift—far exceeding the sector median—provided the fundamental justification for the price pop.
EBS EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: EBS
Why did EBS stock jump?
EBS rose 16.3% from $5.08 to $5.91 after its next-year EPS growth estimate of 191.0% signaled a potential earnings turnaround, with no negative news to counter the bullish revision.
Is EBS a buy after the rally?
The 191.0% EPS growth estimate suggests strong earnings momentum, but the rally may already price in that improvement—investors should watch for actual earnings delivery to confirm.
What caused EBS's surge?
The surge was driven by a sell-side EPS revision showing 191.0% next-year growth, combined with a recovery in the biotech sector.
Why did CRWD stock jump in August 2026?
CRWD jumped 14.5% (from $190.68 to $218.40) after its next-year EPS growth estimate of 26.5% was confirmed by record-breaking quarterly results that reignited Wall Street enthusiasm.
The cybersecurity leader's August 27 earnings release showed accelerating demand for its Falcon platform, with analysts revising estimates upward ahead of the print. The move coincided with a strong week for mega-cap tech, as Nvidia's blowout earnings lifted the Nasdaq, but CRWD's own beat was the primary catalyst for the post-earnings surge.
CRWD EPS revision history → · Screener snapshot from 2026-08-24 →
FAQ: CRWD
Why did CRWD stock jump in August 2026?
CRWD surged 14.5% from $190.68 to $218.40 after posting record-breaking earnings, which validated its 26.5% next-year EPS growth estimate and boosted investor confidence.
Is CRWD a buy after the rally?
The stock's 14.5% gain on strong earnings and a 26.5% EPS growth estimate suggests positive momentum, but the price now reflects higher expectations for continued growth.
What caused CRWD's surge?
Record-breaking Q2 earnings, combined with an upward EPS revision and a favourable tech sector tailwind, drove CRWD's 14.5% rally.
Why did BRZE stock jump in August 2026?
BRZE jumped 12.1% (from $30.80 to $34.53) after its next-year EPS growth estimate of 52.1% on August 25 signaled improving profitability for the customer engagement platform.
The stock benefited from a broader software rally, as investors rotated into high-growth cloud names with visible earnings acceleration. Despite the quiet news tape, the sharp EPS revision—well above the sector average—provided fundamental support for the 12.1% move in just four sessions.
BRZE EPS revision history → · Screener snapshot from 2026-08-25 →
FAQ: BRZE
Why did BRZE stock jump?
BRZE gained 12.1% to $34.53 after analysts raised its next-year EPS growth estimate to 52.1%, highlighting its improving earnings trajectory.
Is BRZE a buy after the rally?
With a 52.1% EPS growth estimate, BRZE offers strong growth potential, but the 12.1% rally may narrow the margin of safety for new buyers.
What is BRZE's EPS growth estimate?
BRZE's current next-year EPS growth estimate stands at 52.1%, reflecting strong anticipated earnings expansion.
Why did HUBS stock jump in August 2026?
HUBS jumped 8.6% (from $240.01 to $260.68) after its next-year EPS growth estimate of 25.9% on August 21 positioned the CRM platform as a steady compounder in a soft macro tape.
The gain came on the back of a positive software sector sentiment, with several peers like Twilio seeing continued adoption. Even without company-specific news, the EPS revision underscored HUBS' ability to grow into its valuation, driving institutional re-accumulation.
HUBS EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: HUBS
Why did HUBS stock jump?
HUBS rose 8.6% to $260.68 after its next-year EPS growth estimate of 25.9% underpinned a reassuring earnings outlook, buoyed by a broadly strong software sector.
Is HUBS a buy after the rally?
With a 25.9% EPS growth estimate, HUBS offers steady growth, but the 8.6% rally means the stock is closer to fair value; consider waiting for pullbacks.
What caused HUBS's surge?
The 8.6% surge was driven by a 25.9% EPS growth revision and improving investor sentiment toward enterprise software.
The standout performers show that upward EPS revisions—even without headline news—can catalyse decisive price moves, especially in small-cap healthcare and high-growth software. These moves signal continued institutional appetite for earnings acceleration, as investors reward names with visible profitability improvements.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →